Quoin Pharmaceuticals, Ltd. (QNRX)
- Previous Close
0.7727 - Open
0.7550 - Bid --
- Ask --
- Day's Range
0.7170 - 0.7900 - 52 Week Range
0.6030 - 12.0000 - Volume
61,778 - Avg. Volume
647,027 - Market Cap (intraday)
2.91M - Beta (5Y Monthly) 1.94
- PE Ratio (TTM)
-- - EPS (TTM)
-9.6400 - Earnings Date Jul 31, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.80
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.
quoinpharma.comRecent News: QNRX
Performance Overview: QNRX
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: QNRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: QNRX
Valuation Measures
Market Cap
2.85M
Enterprise Value
-7.85M
Trailing P/E
1.87
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.50
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-44.03%
Return on Equity (ttm)
-132.92%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-8.69M
Diluted EPS (ttm)
-9.6400
Balance Sheet and Cash Flow
Total Cash (mrq)
10.69M
Total Debt/Equity (mrq)
62.21%
Levered Free Cash Flow (ttm)
-4.68M
Research Analysis: QNRX
Company Insights: QNRX
QNRX does not have Company Insights